Document:

Fifth Supplemental Indenture dated March 3, 2009

 Exhibit 4.2 
  
  
 ONEOK PARTNERS, L.P. 
 Issuer 
 ONEOK PARTNERS INTERMEDIATE
LIMITED PARTNERSHIP 
 Guarantor 
 and 
 WELLS FARGO BANK, N.A. 
 Trustee 
 FIFTH SUPPLEMENTAL INDENTURE 
 Dated as of March 3, 2009 
 to

 INDENTURE 
 relating to Senior Debt Securities 
 Dated as of September 25, 2006 
 8.625% Senior Notes due 2019 
  
  

 TABLE OF CONTENTS 
  

			
	 	  	Page
	 ARTICLE 1 Relation to Indenture; Definitions
	  	1
	 SECTION 1.01. Relation to Indenture.
	  	1
	 SECTION 1.02. Definitions.
	  	1
	 SECTION 1.03. General References.
	  	1
		
	 ARTICLE 2 The Series of Debt Securities
	  	2
	 SECTION 2.01. The Form and Title of the Debt Securities.
	  	2
	 SECTION 2.02. Amount.
	  	2
	 SECTION 2.03. Stated Maturity.
	  	2
	 SECTION 2.04. Interest and Interest Rates.
	  	2
	 SECTION 2.05. Optional Redemption.
	  	2
	 SECTION 2.06. Guarantee.
	  	3
	 SECTION 2.07. Global Securities.
	  	3
		
	 ARTICLE 3 Miscellaneous
	  	3
	 SECTION 3.01. Certain Trustee Matters.
	  	3
	 SECTION 3.02. Continued Effect.
	  	4
	 SECTION 3.03. Governing Law.
	  	4
	 SECTION 3.04. Counterparts.
	  	4

 EXHIBITS 
 Exhibit A: Form of Note 

 FIFTH SUPPLEMENTAL INDENTURE, dated as of March 3, 2009 (this “Supplemental
Indenture”), among ONEOK PARTNERS, L.P., a Delaware limited partnership (the “Partnership”), ONEOK PARTNERS INTERMEDIATE LIMITED
PARTNERSHIP, a Delaware limited partnership (the “Guarantor”), and WELLS FARGO BANK, N.A., as trustee under the Indenture referred to below
(in such capacity, the “Trustee”). 
 RECITALS OF THE PARTNERSHIP 
 WHEREAS, the Partnership and the Trustee have heretofore entered into an Indenture, dated as of September 25, 2006 (the “Original
Indenture”) (the Original Indenture, as amended and supplemented from time to time, including without limitation pursuant to this Supplemental Indenture, being referred to herein as the “Indenture”); and

 WHEREAS, under the Original Indenture, a new series of Debt Securities may at any time be established by the Board of Directors of ONEOK
Partners GP, L.L.C., the Partnership’s general partner (the “General Partner”), in accordance with the provisions of the Original Indenture, and the terms of such series may be established by an indenture supplemental to
the Original Indenture; and 
 WHEREAS, the Partnership proposes to create under the Indenture a new series of Debt Securities; and

 WHEREAS, all acts and things necessary to make the Notes (as herein defined), when executed by the General Partner on behalf of the
Partnership and authenticated and delivered by the Trustee as provided in the Original Indenture and this Supplemental Indenture, and the Guarantee, when executed by the general partner of the Guarantor on behalf of the Guarantor, the valid and
binding obligations of the Partnership and the Guarantor and to make this Supplemental Indenture a valid and binding agreement in accordance with the Original Indenture have been done or performed; 
 NOW, THEREFORE, in consideration of the premises, agreements and obligations set forth herein and for other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the parties hereto hereby agree, for the equal and proportionate benefit of all Holders of the Notes, as follows: 
 ARTICLE 1 
 RELATION TO INDENTURE;
DEFINITIONS 
 SECTION 1.01. Relation to Indenture. 
 With respect to the Notes, this Supplemental Indenture constitutes an integral part of the Indenture. 
 SECTION 1.02. Definitions. 
 For all purposes of this Supplemental Indenture, capitalized terms used herein and not otherwise defined herein shall have the meanings assigned thereto in the Original Indenture. 
 SECTION 1.03. General References. 
 All references in this Supplemental Indenture to Articles and Sections, unless otherwise specified, refer to the corresponding Articles and Sections of this Supplemental Indenture; and the term
“herein”, “hereof”, “hereunder” and any other word of similar import refers to this Supplemental Indenture. 

 ARTICLE 2 
 THE SERIES OF DEBT SECURITIES 
 SECTION 2.01. The Form and Title of the Debt Securities. 
 There is hereby established a new series of Debt
Securities to be issued under the Indenture and to be designated as the Partnership’s 8.625% Senior Notes due 2019 (the “Notes”). The Notes shall be substantially in the form attached as Exhibit A hereto, in each
case with such appropriate insertions, omissions, substitutions and other variations as are required or permitted by the Indenture, and may have such letters, numbers or other marks of identification and such legends or endorsements placed thereon
as the Partnership may deem appropriate or as may be required or appropriate to comply with any laws or with any rules made pursuant thereto or with the rules of any securities exchange or automated quotation system on which the Notes may be listed
or traded, or to conform to general usage, or as may, consistently with the Indenture, be determined by the officers executing such Notes, as evidenced by their execution thereof. 
 The Notes shall be executed, authenticated and delivered in accordance with the provisions of, and shall in all respects be subject to, the terms,
conditions and covenants of the Original Indenture as supplemented by this Supplemental Indenture (including the form of Note set forth as Exhibit A hereto (the terms of which are incorporated in and made a part of this Supplemental Indenture
for all intents and purposes)). 
 SECTION 2.02. Amount. 
 The aggregate principal amount of the Notes which may be authenticated and delivered pursuant hereto is unlimited. The Trustee shall initially
authenticate and deliver Notes for original issue in an initial aggregate principal amount of up to $500,000,000 upon delivery to the Trustee of a Partnership Order for the authentication and delivery of such Notes. The aggregate principal amount of
the Notes to be issued hereunder may be increased at any time hereafter and the series may be reopened for issuances of additional Notes upon Partnership Order without the consent of any Holder. The Notes issued on the date hereof and any such
additional Notes that may be issued hereafter shall be part of the same series of Debt Securities for all purposes under the Indenture. 
 SECTION 2.03. Stated Maturity. 
 The Notes may be issued on any Business Day on or after March 3, 2009,
and the Stated Maturity of the Notes shall be March 1, 2019. 
 SECTION 2.04. Interest and Interest Rates.

 The rate or rates at which the Notes shall bear interest, the date or dates from which such interest shall accrue, the interest payment
dates on which any such interest shall be payable and the regular record date for any interest payable on any interest payment date, in each case, shall be as set forth in the form of Note set forth as Exhibit A hereto. 
 SECTION 2.05. Optional Redemption. 
 At its option, the Partnership may redeem the Notes, in whole or in part, in principal amounts of $2,000 and in multiples of $1,000 in excess thereof, at any time or from time to time, at the applicable redemption
price determined as set forth in the form of Note attached hereto as Exhibit A, in accordance with the terms set forth in the Notes and in accordance with Article III of the Original Indenture. 
  

 2 

 SECTION 2.06. Guarantee. 
 Except as provided below, Article XII of the Original Indenture shall apply to the Notes. For the purposes of this Supplemental Indenture and the Notes
(including without limitation the provisions of the Original Indenture to the extent applicable thereto), the term “Guarantor” shall mean ONEOK Partners Intermediate Limited Partnership, a Delaware limited partnership, and any
successor Person thereto under the Indenture. 
 With respect to the Notes, paragraph (a) of Section 12.04 of the Original
Indenture is hereby amended and restated in its entirety as set forth below; provided, however that the amendment and restatement set forth below in this Section 2.06 shall apply only to the Notes and not to any other series of Debt
Securities issued under the Original Indenture: 
 “(a) Notwithstanding anything to the contrary in this Article XII, if any Guarantor
shall cease to be a Subsidiary of the Partnership, then, if no Default or Event of Default shall have occurred and be continuing, such Guarantor, upon giving notice to the Trustee to the foregoing effect, shall be deemed to be released from all of
its obligations under this Indenture, and the Guarantee shall be of no further force or effect with respect to such Guarantor. Following the receipt by the Trustee of any such notice, the Partnership shall cause this Indenture to be amended as
provided in Section 9.01(l) hereof; provided, however, that the failure to so amend this Indenture shall not affect the validity of the termination of the Guarantee with respect to such Guarantor.” 
 The Guarantor’s address and telecopier number for the purposes of Section 13.03 of the Original Indenture is: 
 ONEOK Partners Intermediate Limited Partnership 

	 	c/o	ONEOK Partners GP, L.L.C. 

 100 West Fifth Street, Suite
1831 
 Tulsa, Oklahoma 74103-4298 
 Telecopier No.: (918) 588-7800 
 Attention: Chief Financial Officer 
 SECTION 2.07. Global Securities. 
 The Notes shall initially be issuable in whole or in part in the form of one or more Global Securities. Such Global Securities (i) shall be deposited with, or on behalf of, The Depository Trust Company, which
shall act as Depositary with respect to the Notes, (ii) shall bear the legends applicable to Global Securities set forth in Section 2.15(a) of the Original Indenture, (iii) may be exchanged in whole or in part for Notes in definitive
form upon the terms and subject to the conditions provided in Section 2.15(b) of the Original Indenture and in this Supplemental Indenture and (iv) shall otherwise be subject to the applicable provisions of the Indenture. 
 ARTICLE 3 
 MISCELLANEOUS 
 SECTION 3.01. Certain Trustee Matters. 
 The recitals contained herein shall be taken as the statements of the Partnership, and the Trustee assumes no responsibility for their correctness.

 The Trustee makes no representations as to the validity or sufficiency of this Supplemental Indenture, the Guarantee or the Notes or the
proper authorization or the due execution hereof or thereof by the Partnership or the Guarantor. 
  

 3 

 Except as expressly set forth herein, nothing in this Supplemental Indenture shall alter the duties,
rights or obligations of the Trustee set forth in the Original Indenture. 
 The Trustee makes no representation or warranty as to the
validity or sufficiency of the information contained in the prospectus supplement related to the Notes, except such information which specifically pertains to the Trustee itself, or any information incorporated therein by reference. 
 SECTION 3.02. Continued Effect. 
 Except as expressly supplemented and amended by this Supplemental Indenture, the Original Indenture shall continue in full force and effect in accordance with the provisions thereof, and the Original Indenture (as
supplemented and amended by this Supplemental Indenture) is in all respects hereby ratified and confirmed. This Supplemental Indenture and all its provisions shall be deemed a part of the Original Indenture in the manner and to the extent herein and
therein provided. 
 SECTION 3.03. Governing Law. 
 This Supplemental Indenture and the Notes shall be governed by and construed in accordance with the laws of the State of New York. 
 SECTION 3.04. Counterparts. 
 This instrument may be executed in any number of counterparts, each of which, when delivered, shall be deemed to be an original, but all such counterparts shall together constitute but one and the same instrument.

 (Signature Page Follows) 
  

 4 

 IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly executed and
delivered, all as of the day and year first above written. 
  

			
	ONEOK PARTNERS, L.P.
		
	By:	 	 ONEOK Partners GP, L.L.C.,
 its General
Partner

		
	By:	 	 /s/ Curtis Dinan

	Name:	 	 Curtis Dinan

	Title:	 	 Executive Vice President, Chief Financial Officer and Treasurer

	
	ONEOK PARTNERS INTERMEDIATE LIMITED PARTNERSHIP
		
	By:	 	 ONEOK ILP GP, L.L.C.,
 its General
Partner

		
	By:	 	 /s/ Curtis Dinan

	Name:	 	 Curtis Dinan

	Title:	 	 Executive Vice President, Chief Financial Officer and Treasurer

	
	WELLS FARGO BANK, N.A.,
	as Trustee
		
	By:	 	 /s/ Gregory S. Clarke

	Name:	 	 Gregory S. Clarke

	Title:	 	 Vice President

 Fifth Supplemental Indenture Signature Page 

 EXHIBIT A 
 [FORM OF FACE OF NOTE] 
 [If a Global Security, insert—UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED
REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION (“DTC”), NEW YORK, NEW YORK, TO THE PARTNERSHIP OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF
CEDE & CO. OR SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO., OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE OR
OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN.] 
 [If a Global Security, insert—TRANSFERS OF THIS GLOBAL SECURITY SHALL BE LIMITED TO TRANSFERS IN WHOLE, BUT NOT IN PART, TO NOMINEES OF DTC OR TO A SUCCESSOR THEREOF OR SUCH SUCCESSOR’S NOMINEE, AND TRANSFERS OF PORTIONS OF
THIS GLOBAL SECURITY SHALL BE LIMITED TO TRANSFERS MADE IN ACCORDANCE WITH THE RESTRICTIONS SET FORTH IN THE INDENTURE REFERRED TO HEREIN.] 
 ONEOK PARTNERS, L.P. 
 8.625% Senior Note due 2019 
  

			
	 No.             
	  	U.S.$                    
		
	 CUSIP No. 68268NAE3
	  	

 ONEOK PARTNERS, L.P., a Delaware limited partnership (herein called the “Partnership”,
which term includes any successor Person under the Indenture hereinafter referred to), for value received, hereby promises to pay to
                                        , or
registered assigns, the principal sum of
                                         United
States Dollars on March 1, 2019, and to pay interest thereon from March 3, 2009, or from the most recent interest payment date to which interest has been paid or duly provided for, semi-annually on March 1 and September 1 in each
year, commencing on September 1, 2009, at the rate of 8.625% per annum, until the principal hereof is paid or made available for payment and at the same rate per annum on any overdue principal and premium and on any overdue installment of
interest. The amount of interest payable for any period shall be computed on the basis of twelve 30-day months and a 360-day year. The amount of interest payable for any partial period shall be computed on the basis of a 360-day year of twelve
30-day months and the days elapsed in any partial month. In the event that any date on which interest is payable on this Note is not a Business Day, then a payment of the interest payable on such date will be made on the next succeeding day which is
a Business Day (and without any interest or other payment in respect of any such delay) with the same force and effect as if made on the date the payment was originally payable. The interest so payable, and punctually paid or duly provided for, on
any interest payment date will, as provided in such Indenture, be paid to the Person in whose name this Note (or one or more predecessor Notes) is registered at the close of business on the regular record date for such interest, which record date
shall be the February 15 or August 15 (whether or not a Business Day), as the case may be, next preceding such interest payment date. Any such interest not so punctually paid or duly provided for shall forthwith cease to be payable to the
Holder on such regular record date and may either be paid to the Person in whose name this Note (or one or more predecessor Notes) is registered at the close of business on a special record date for the payment of such Defaulted Interest to be fixed
by the Trustee, notice of which shall be given to Holders of Notes not less than 10 days prior to such special record date, or be paid at any time in any other lawful manner not inconsistent with the requirements of any securities exchange or
automated quotation system on which the Notes may be listed or traded, and upon such notice as may be required by such exchange or automated quotation system, all as more fully provided in the Indenture. 
 [If a Global Security, insert—Payment of the principal of (and premium, if any) and any such interest on this Note will be made by transfer of
immediately available funds to a bank account in the United States of America designated by the Holder to the Paying Agent in U.S. Dollars.] 
  

 A-1 

 [If a definitive Debt Security, insert—Payment of the principal of (and premium, if any) and any
such interest on this Note will be made at the office or agency of the Partnership maintained for that purpose in U.S. Dollars or subject to any laws or regulations applicable thereto and to the right of the Partnership (as provided in the
Indenture) to rescind the designation of any such Paying Agent, at the offices of                     , and at such other offices or agencies as the
Partnership may designate, by U.S. Dollar check drawn on, or transfer to a U.S. Dollar account maintained by the payee with, a bank in The City of New York (so long as the applicable Paying Agent has received proper transfer instructions
in writing at least 10 days prior to the payment date); provided, however, that payment of interest may be made at the option of the Partnership by U.S. Dollar check mailed to the addresses of the Persons entitled thereto as such
addresses shall appear in the Debt Security Register or by transfer to a U.S. Dollar account maintained by the payee with a bank in The City of New York (so long as the applicable Paying Agent has received proper transfer instructions in
writing by the record date prior to the applicable interest payment date).] 
 Reference is hereby made to the further provisions of this
Note set forth on the reverse hereof, which further provisions shall for all purposes have the same effect as if set forth at this place. 
 Unless the certificate of authentication hereon has been executed by the Trustee referred to on the reverse hereof by manual signature, this Note shall not be entitled to any benefit under the Indenture or be valid or obligatory for any
purpose. 
 IN WITNESS WHEREOF, the Partnership has caused this instrument to be duly executed. 
 Dated:                     ,
         
  

					
	 ONEOK PARTNERS, L.P.

		
	 By:
	 	 ONEOK Partners GP, L.L.C.
 its General Partner

			
		 	 By:
	 	  

		 	 Name:
	 	  

		 	 Title:
	 	  

  

 A-2 

 TRUSTEE’S CERTIFICATE OF AUTHENTICATION 
 This is one of the Debt Securities of the series designated therein referred to in the within-mentioned Indenture. 
  

			
	 WELLS FARGO BANK, N.A.,
 as
Trustee

		
	By:	 	  

		 	Authorized Signatory

  

 A-3 

 [REVERSE OF NOTE] 
 ONEOK PARTNERS, L.P. 
 8.625% Senior Note due 2019 
 This security is one of a duly authorized issue of debt securities of the Partnership (the “Debt Securities”), issued and to be issued in one
or more series under an Indenture dated as of September 25, 2006, as amended and supplemented to date, including without limitation by the Fifth Supplemental Indenture thereto, dated as of March 3, 2009 (such Indenture, as so amended and
supplemented being referred to herein as the “Indenture”), between the Partnership and Wells Fargo Bank, N.A., as Trustee (the “Trustee,” which term includes any successor trustee under the Indenture), to which Indenture and all
indentures supplemental thereto reference is hereby made for a statement of the respective rights, limitations of rights, obligations, duties and immunities thereunder of the Partnership, the Trustee and the Holders of the Debt Securities and of the
terms upon which the Debt Securities are, and are to be, authenticated and delivered. This Debt Security is one of the series designated on the face hereof. The Debt Securities of this series are referred to herein as the “Notes.”

 The Notes will be subject to redemption at any time at the option of the Partnership, in whole or in part, at a redemption price equal to
the principal amount of the Notes to be redeemed, plus any accrued and unpaid interest thereon to the applicable Redemption Date (subject to the right of holders of record on the relevant record date to receive interest due on an Interest Payment
Date that is on or prior to the Redemption Date) plus the “Make-Whole Premium” as defined below. 
 The “Make-Whole
Premium” or “premium” with respect to any Note to be redeemed shall be equal to the excess, if any, of: (a) the sum of the present values, calculated as of the Redemption Date, of (i) each interest payment that, but for such
redemption, would have been payable on the Note or portion thereof being redeemed on each interest payment date occurring after the Redemption Date (excluding any accrued interest for the period prior to the Redemption Date); and (ii) the
principal amount that, but for such redemption, would have been payable at the final maturity of the Note being redeemed; over (b) the principal amount of the Note being redeemed. 
 The present values of interest and principal payments referred to in clause (a) of the immediately preceding paragraph will be determined in
accordance with generally accepted principles of financial analysis. These present values will be calculated by discounting the amount of each payment of interest or principal from the date that each such payment would have been payable, but for the
redemption, to the Redemption Date at a discount rate equal to the Comparable Treasury Yield (as defined below) plus 50 basis points. The Make-Whole Premium will be calculated by an independent investment banking institution of national standing
appointed by the Partnership. If the Partnership fails to appoint an independent investment banker not less than 30 days prior to the Redemption Date, or if such independent investment banker is unwilling or unable to make the calculation, the
calculation will be made by SunTrust Robinson Humphrey, Inc., J.P. Morgan Securities Inc. and Greenwich Capital Markets, Inc. If SunTrust Robinson Humphrey, Inc., J.P. Morgan Securities Inc. and Greenwich Capital Markets, Inc. are unwilling or
unable to make the calculation, the Partnership will appoint an independent investment banking institution of national standing to make the calculation. 
 For purposes of determining the Make-Whole Premium, “Comparable Treasury Yield” means a rate of interest per annum equal to the weekly average yield to maturity of United States Treasury Securities that have
a constant maturity that corresponds to the remaining term to maturity of the Notes, calculated to the nearest 1/12th of a year. The Comparable Treasury Yield will be determined as of the third business day immediately preceding the applicable
Redemption Date, and prior to the Redemption Date the Partnership shall deliver to the Trustee an Officers’ Certificate setting forth the redemption price and showing the calculation thereof in reasonable detail. 
 The weekly average yields of United States Treasury Securities will be determined by reference to the most recent statistical release published by the
Federal Reserve Bank of New York and designated “H.15(519) Selected Interest Rates” or any successor release. If the H.15 statistical release sets forth a weekly average yield for United States Treasury Securities having a constant
maturity that is the same as the remaining term calculated as set forth above, then the Comparable Treasury Yield will be equal to such weekly average yield. In all other cases, the Comparable Treasury Yield will be calculated by interpolation on a
straight-line basis between the weekly average yields on the United States Treasury Securities that have a constant maturity closest to and greater than the remaining term and the United States Treasury Securities that have a constant maturity
closest to and less than the remaining term (in each case as set forth in the H.15 statistical release or any successor release). Any weekly 

  

 A-4 

 
average yields calculated by interpolation will be rounded to the nearest 1/100th of 1%, with any figure of 1/200th of 1% or above being rounded upward. If
weekly average yields for United States Treasury Securities are not available in the H.15 statistical release or otherwise, then the Comparable Treasury Yield will be calculated by interpolation of comparable rates selected by an independent
investment banking institution of national standing selected in the manner described in the second preceding paragraph. 
 Unless the
Partnership defaults in payment of the redemption price, on and after the date of redemption, interest will cease to accrue on this Note or the portions hereof called for redemption. 
 In the event of redemption of this Note in part only, a new Note or Notes of like tenor for the unredeemed portion hereof will be issued in the name of
the Holder hereof upon the cancellation hereof. 
 The Indenture contains provisions for defeasance at any time of (1) the entire
indebtedness of this Note or (2) certain restrictive covenants and Events of Default with respect to this Note, in each case upon compliance with certain conditions set forth in the Indenture. 
 If an Event of Default with respect to the Notes shall occur and be continuing, the principal of the Notes may be declared due and payable in the manner
and with the effect provided in the Indenture. 
 The Indenture permits, with certain exceptions as therein provided, the amendment thereof
and the modification of the rights and obligations of the Partnership, the Guarantor and the rights of the Holders of the Debt Securities of each series to be affected under the Indenture at any time by the Partnership, the Guarantor and the Trustee
with the consent of not less than the Holders of a majority in principal amount of the Outstanding Debt Securities of each series to be affected. The Indenture also contains provisions permitting the Holders of a majority in principal amount of the
Outstanding Debt Securities of each affected series, on behalf of the Holders of all Debt Securities of such series, to waive compliance by the Partnership and the Guarantor with certain provisions of the Indenture. The Indenture permits, with
certain exceptions as therein provided, the Holders of a majority in principal amount of Debt Securities of any series then Outstanding to waive past defaults under the Indenture with respect to such series and their consequences. Any such consent
or waiver by the Holder of this Note shall be conclusive and binding upon such Holder and all holders of Notes of which this Note is a predecessor Note, whether or not notation of such consent or waiver is made upon this or any other Note.

 As provided in and subject to the provisions of the Indenture, the Holder of this Note shall not have the right to institute any action or
proceeding with respect to the Indenture or for the appointment of a receiver or trustee or for any other remedy thereunder, unless such Holder shall have previously given the Trustee written notice of a continuing Event of Default with respect to
the Notes, the Holders of not less than 25% in aggregate principal amount of the Notes at the time Outstanding shall have made written request to the Trustee to institute proceedings in respect of such Event of Default and offered the Trustee
reasonable indemnity or security as required by the Trustee and the Trustee shall not have received from the Holders of a majority in principal amount of Notes at the time Outstanding a direction inconsistent with such request, and the Trustee shall
have failed to institute any such proceeding for 60 days after receipt of such notice, request and offer of indemnity or security. The foregoing shall not apply to any suit instituted by the Holder of this Note for the enforcement of any payment of
principal hereof or any premium or interest hereon on or after the respective due dates expressed herein. 
 No reference herein to the
Indenture and no provision of this Note or of the Indenture shall alter or impair the obligation of the Partnership, which is absolute and unconditional, to pay the principal of and any premium and interest on this Note at the times, place(s) and
rate, and in the currency, herein prescribed. 
 [If a Global Security, insert—This Global Security or portion hereof may not be
exchanged for definitive Debt Securities of this series except in the limited circumstances provided in the Indenture. 
 The holders of
beneficial interests in this Global Security will not be entitled to receive physical delivery of definitive Debt Securities except as described in the Indenture and will not be considered the Holders thereof for any purpose under the Indenture.]

 [If a definitive Debt Security, insert—As provided in the Indenture and subject to certain limitations therein set forth, the
transfer of this Note is registerable in the Debt Security Register, upon surrender of this Note for registration of transfer at the office or agency of the Partnership in The City of New York, or, subject to any laws or 

  

 A-5 

 
regulations applicable thereto and to the right of the Partnership (limited as provided in the Indenture) to rescind the designation of any such transfer
agent, at the offices of                          in the Borough of Manhattan, The City of New York, and at such other offices or
agencies as the Partnership may designate, duly endorsed by, or accompanied by a written instrument of transfer in form satisfactory to the Partnership and the Debt Security Registrar duly executed by, the Holder hereof or his attorney duly
authorized in writing, and thereupon one or more new Notes of like tenor, of authorized denominations and for the same aggregate principal amount, will be issued to the designated transferee or transferees.] 
 The Notes are issuable only in registered form without coupons in denominations of $2,000 and any integral multiple of $1,000 in excess thereof. As
provided in the Indenture and subject to certain limitations therein set forth, Notes are exchangeable for a like aggregate principal amount of Notes and of like tenor of a different authorized denomination, as requested by the Holder surrendering
the same. 
 No service charge shall be made for any such registration of transfer or exchange, but the Partnership may require payment of a
sum sufficient to cover any tax or other governmental charge payable in connection therewith. 
 Prior to due presentment of this Note for
registration of transfer, the Partnership, the Guarantor, the Trustee and any agent of the Partnership, the Guarantor or the Trustee may treat the Person in whose name this Note is registered as the owner hereof for all purposes, whether or not this
Note is overdue, and neither the Partnership, the Guarantor, the Trustee nor any such agent shall be affected by notice to the contrary. 
 Obligations of the Partnership and the Guarantor under the Indenture and the Debt Securities thereunder, including this Note, are non-recourse to ONEOK Partners GP, L.L.C. (the “General Partner”) and ONEOK ILP GP, L.L.C. (the
“Guarantor General Partner”) and their respective Affiliates (other than the Partnership and the Guarantor), and payable only out of cash flow and assets of the Partnership and the Guarantor. The Trustee, and each Holder of a Debt Security
by its acceptance thereof, will be deemed to have agreed in the Indenture that (1) none of the General Partner, the Guarantor General Partner and their respective assets (nor any of their respective Affiliates, other than the Partnership and
the Guarantor, or their respective assets) shall be liable for any of the obligations of the Partnership or the Guarantor under the Indenture or such Debt Securities, including this Note, and (2) no director, officer, employee, stockholder or
unitholder, as such, of the Partnership, the Guarantor, the Trustee, the General Partner, the Guarantor General Partner or any Affiliate of any of the foregoing entities shall have any personal liability in respect of the obligations of the
Partnership or the Guarantor under the Indenture or such Debt Securities by reason of his, her or its status. 
 This Note shall be governed
by and construed in accordance with the laws of the State of New York. 
 All terms used in this Note which are defined in the Indenture
shall have the meanings assigned to them in the Indenture. 
  

 A-6 

 [If a definitive Debt Security, insert as a separate page— 
 FOR VALUE RECEIVED, the undersigned hereby sell(s), assign(s) and transfer(s) unto
                                         (Please
Print or Typewrite Name and Address of Assignee) the within instrument of ONEOK PARTNERS, L.P. and does hereby irrevocably constitute and appoint
                                         Attorney
to transfer said instrument on the books of the within-named Partnership, with full power of substitution in the premises. 
 Please Insert Social Security
or 
 Other Identifying Number of Assignee: 
  

							
	  
	 		  	  

				
	Dated:	 	  
	 		  	  

		 		 		  	(Signature)

  

			
		
	Signature Guarantee:	 	  

 (Participant in a Recognized Signature 
 Guaranty Medallion Program) 
 NOTICE: The signature to this assignment must correspond
with the name as written upon the face of the within instrument in every particular, without alteration or enlargement or any change whatever.] 
  

 A-7 

 [If a Global Security, insert as a separate page— 
 SCHEDULE OF INCREASES OR DECREASES IN GLOBAL SECURITY 
 The following increases or decreases in this Global Security have been made: 
  

									
	 Date of Exchange
	  	 Amount of
 Decrease in
 Principal
 Amount of this Global
Security
	  	 Amount of
 Increase in
 Principal Amount
 of this
 Global
Security
	  	 Principal Amount
 of this Global
 Security following

 such decrease
 (or
increase)
	  	 Signature of
 authorized officer
 of Trustee or
 Depositary

  

 A-8 

 NOTATION OF GUARANTEE 
 The Guarantor (which term includes any successor person under the Indenture dated as of September 25, 2006 (as amended and supplemented from time to
time, the “Indenture”) between ONEOK Partners, L.P., a Delaware limited partnership (the “Partnership”), and Wells Fargo Bank, N.A., as trustee (the “Trustee”)), has fully,
unconditionally and absolutely guaranteed, to the extent set forth in the Indenture and subject to the provisions in the Indenture, the due and punctual payment of the principal of, premium, if any, and interest on the Notes and all other amounts
due and payable under the Indenture and the Notes by the Partnership. 
 The obligations of the Guarantor to the Holders of Notes and to the
Trustee pursuant to the Guarantee are expressly set forth in Article XII of the Indenture and reference is hereby made to the Indenture for the precise terms of the Guarantee. Capitalized terms used but not defined herein have the meanings given to
them in the Indenture. 
  

			
	ONEOK PARTNERS INTERMEDIATE LIMITED PARTNERSHIP
		
	By:	 	 ONEOK ILP GP, L.L.C.,
 its General
Partner

		
	By:	 	  

	Name:	 	  

	Title:	 	  

  

 A-9License Agreement

 Exhibit 10.55 
 ***Text Omitted and Filed Separately 
 with the Securities and Exchange Commission. 

Confidential Treatment Requested 
 Under 17 C.F.R. Sections 200.80(b)(4) 
 and 240.24b-2. 
 LICENSE AGREEMENT 
 THIS AGREEMENT entered into this 29th day of April, 1991
(“Effective Date”) between Life Technologies, Inc., a Delaware corporation having its principal place of business at 8400 Helgerman Court, Gaithersburg, Maryland 20877 (“LTI”) and Vical Incorporated, a Delaware corporation,
having its principal place of business at 9373 Towne Center Drive. Suite 100, San Diego, California 92121 (“Vical”). 
 WHEREAS,
LTI is a manufacturer and distributor of a wide range of biological and testing products and is desirous of expanding its product offerings of compounds in the research products market; and 
 WHEREAS, Vical has developed and has proprietary rights in certain compounds; and 
 WHEREAS, LTI is desirous of obtaining an exclusive license to make, have made, use, and sell such compounds which Vical has developed or in which it has
proprietary rights; 
 NOW, THEREFORE, in consideration of the mutual covenants herein and for other good and valuable consideration, LTI and
Vical agree as follows: 
 ARTICLE I – DEFINITIONS 
 As used in this Agreement, the following terms shall have the meaning stated opposite each term: 
 1.1 “Licensed Patent(s)” shall mean any patent which may issue from Vical’s U.S. patent application Serial No. 07/511,219, filed
April 19, 1990 and any divisions, continuations, continuations-in-part, or reissues thereof or any foreign patents deriving priority therefrom. 
 1.2 “Licensed Product(s)” shall mean any compounds, including, but not limited to, DORI and DORI/CHOL 7/3, covered by the Licensed Technology. 
 1.3 “The Field” shall mean the research products market, including, but not limited to, protein delivery systems, bulk quantities for
industrial use, and all research applications 
 1.4 “Know-how” shall mean any unpatented Vical knowledge or technology related to
the Licensed Patent(s) existing as of the Effective date. 
 1.5 “Improvements” shall mean any inventions, improvements or
discoveries, on or related to the Know-how or the Licensed Patents. 
  

 1 

 a) “Vical Improvements” shall mean those Improvements made solely by Vical during the term of
this Agreement. 
 b) “LTI Improvements” shall mean those Improvements made solely by LTI during the term of this Agreement.

 c) “Joint Improvements” shall mean those Improvements jointly made by LTI and Vical during the term of this Agreement.

 1.6 “Joint Improvement Product(s)” shall mean any compounds covered by the Joint Improvements. 
 1.7 “Licensed Technology” shall mean the Licensed Patent(s), Know-how, and Vical Improvements. 
 1.8 “Therapeutic Product(s)” means products which have received, or are intended to receive approval or clearance by the agency or agencies
having authority to grant the right to commercialize (sales and promotion) such products for in vitro or in vivo therapeutic use in the United States. 
 1.9 “LTI” shall include any corporation or other business entity controlled by, controlling, or under common control with LTI. For this purpose, “control” means direct or indirect beneficial
ownership of at least fifty percent (50%) interest in the shares of all classes of its voting stock, or possession of the direct power to direct or cause the direction of management and policies of the corporation or other business entity.

 1.10 “Net Sales” shall mean the gross invoiced selling price of the Licensed Product(s) in the form in which they are sold, less
the following items but only insofar as they actually pertain to the sale of such Licensed Product(s) by LTI and are included in such gross selling price, 
 a) to the extent such items (except items (i) and (vi)) are separately billed; 
 i) Usual trade
discounts actually allowed (other than advertising allowances, fees, or commissions to any employee); 
 ii) Packing costs; 
 iii) Import, export, excise, sales and value-added taxes, and customs duties; 
 iv) Costs of insurance and transportation from the place of manufacture to the customer’s premises or point of installation; 
  

 2 

 v) Costs of installation at the place of use; and 
 vi) Credit for returns, allowances, or trade discounts; and 
 b) provided, however, if Licensed Product(s) are sold in combination with other products, Net Sales for computing royalty payments under this Agreement, shall be determined by multiplying the Net Sales of such
combination by a fraction, the numerator of which is the selling price of the Licensed Product(s) contained in such combination if the Licensed Product(s) were sold separately and the denominator of which is the selling price of the combination.

 1.11 “Sublicense Income” shall mean the gross amount received by LTI, directly or indirectly, from sublicensees for or on
account of any of the rights granted hereunder. 
 ARTICLE II – GRANT 
 2.1 Vical hereby grants to LTI an exclusive, world-wide right and license to use the Licensed Technology to make, have made, use and sell the Licensed
Product(s) in the Field, subject only to Vical’s retained right to: 
 a) [***]; 
 b) [***]; and 
 c) [***]. 
 2.2. Each of the parties hereto hereby grants to the other a certain [***], to use its individual interest in the Joint Improvements to [***] in
accordance with the limitations set forth below: 
 a) in the case of LTI, [***]; and 
 b) in the case of Vical, [***]. 
 2.3 LTI
shall have the right to sublicense the rights granted hereunder on terms substantially similar to the terms herein. All sublicenses hereunder granted by LTI shall be coterminable with this Agreement, and this fact shall be stated in any such
sublicense agreement. LTI shall have responsibility for the royalty reporting activities of a sublicensee as if the activities were those of LTI. LTI shall promptly provide Vical with a copy of any sublicense issued hereunder. 
 2.4 Concurrently with the execution of this Agreement, Vical shall hereby assign to LTI all of its right, title, interest, and all goodwill represented
therein, in its marks, “Superfectin” and “Turbofectin,” but only insofar as such right, title, interest, and goodwill pertains to use of the Licensed Product(s) in the Field. 
  
  

	***	Confidential Treatment Requested 

  

 3 

 ARTICLE III – DISCLOSURE OF KNOW-HOW 
 3.1 Within thirty (30) days of execution of this Agreement, Vical will provide LTI with a copy of all Know-how related to production methodologies
and protocols in its possession and thereafter during the term of this Agreement will: 
 a) Advise LTI of any Vical Improvements within
thirty (30) days of the recognized discovery thereof; 
 b) Make available its personnel, upon reasonable request, to assist LTI
personnel in understanding and utilizing the Licensed Technology; 
 c) Allow LTI, upon reasonable notice, during business hours, to enter
upon Vical’s premises and observe Vical’s efforts related solely to the Licensed Technology, and, only during business hours for reasonable periods of time, to confer with appropriate Vical research personnel in furtherance of this
Agreement; and 
 d) Provide training to at least [***] of LTI’s employees, but no more than [***], designated by LTI as essential,
after consultation with and reasonable agreement by Vical, to LTI’s efforts to utilize the Licensed Technology. 
 ARTICLE IV
– CONSULTING 
 Vical shall make available to LTI the consulting services of [***] or a mutually agreed-upon substitute, who
shall visit LTI’s facilities, no more than four (4) mutually-agreed upon person days per year, upon LTI’s reasonable request and expense, during the term of this Agreement. 
 ARTICLE V – TERM OF LICENSE 
 5.1 The term of this Agreement shall
commence upon the Effective Date and shall terminate on a country-by-country basis upon: 
 a) The termination of the life of the Licensed
Patent(s) in such country, or the expiration of the term of the pendency of an application for a Licensed Patent(s) in such country, but 
 b) Should no Licensed Patent(s) issue or no application for a Licensed Patent(s) be filed in any country, the term of the Agreement in that country shall be [***] from the date of first commercial sale. 
  
  

	***	Confidential Treatment Requested 

  

 4 

 ARTICLE VI – PAYMENTS 
 As consideration for the rights granted by Vical to LTI hereunder: 
 6.1 LTI shall pay a technology transfer
fee of [***] to Vical within thirty (30) days of execution of this Agreement and shall pay Vical an additional fee of [***] on or before [***]. 
 6.2 LTI shall pay earned royalties to Vical based upon LTI’s Net Sales, the amount of which royalties shall be determined in the following manner: 
 a) If Licensed Product(s) are manufactured or sold in a country: 
 i) where no Licensed Patent(s) exists; or 
 ii) where no application(s) for a Licensed Patent(s) is pending
after [***] from the Effective Date; or 
 iii) where a Licensed Patent(s) has been declared invalid in such country by a court of competent
jurisdiction through no fault of LTI, then LTI shall pay royalties at the rate of [***] of Net Sales in such country until such time as a competitor enters the market in such country utilizing technology falling within the scope of the Licensed
Patent(s) making such payments by LTI commercially unfeasible, then LTI shall serve notice to Vical of such event. Should Vical fail to successfully dispute or disprove such event within thirty (30) days, then no royalty shall be payable by
LTI. 
 b) If Licensed Product(s) are manufactured or sold in a country: 
 i) where a Licensed Patent(s) exists; or 
 ii) where an application for a Licensed Patent(s) is pending; or 
 iii) where less than [***] have passed from Effective Date in
any event, 
 then LTI shall pay royalties at the rate of [***] of Net Sales in such country. 
 6.3 LTI shall pay to Vical royalties equaling [***] of Sublicense Income. 
 6.4 LTI shall pay Vical minimum annual royalties in the amount of [***] for each of the [***] of this Agreement upon the [***] of the Effective Date. Amounts paid by LTI under Sections 6.2 and 6.3 shall be credited
against the relevant minimum annual royalty due, and any excess amount paid shall be credited against succeeding minimum annual royalty obligations. 
  
  

	***	Confidential Treatment Requested 

  

 5 

 6.5 LTI shall make a bonus payment of [***] to Vical upon the earlier to occur of the following during
the term of this Agreement: 
 a) Vical develops a product which LTI desires to market utilizing the Licensed Technology or technology which
is covered by the License Agreement dated and effective as of April 20, 1990 by and between LTI and Vical (the “Prior Agreement Technology”), which product is limited to use in protein delivery systems during the term of this
Agreement; or 
 b) LTI actively promotes the Licensed Product(s) or the Prior Agreement Technology for use in protein delivery systems
during the term of this Agreement. 
 ARTICLE VII – REPORTS 
 7.1 Within sixty (60) days after the end of each calendar quarter during the term of this Agreement, LTI shall furnish Vical a written report
setting forth the Net Sales and royalties payable thereon and the amount of Sublicense Income received, accompanied by payment of such royalties, including royalties payable on Sublicense Income. All royalties shall be paid to Vical in U.S. dollars,
and in full. In the event that conversion from foreign currency is required in calculating a royalty payment hereunder, the exchange rate used shall be the rate in effect at the end of the last business day of the month just prior to the date
payment is required to be made hereunder as published in the Wall Street Journal. 
 7.2 LTI shall prepare a final report and payment within
sixty (60) days after the date of termination of this Agreement and within sixty (60) days after the final sale of Licensed Product(s) left in its inventory after termination of this Agreement in accordance with Section 12.4 below.
Such report shall include a summary of existing inventory and any royalties payable as of the date of termination or after such date in accordance with Section 12.4 below. 
 ARTICLE VIII – BOOKS AND RECORDS 
 LTI and its sublicensees shall
keep and maintain complete and accurate records and books of account in sufficient detail and form so as to enable verification of royalties payable by LTI hereunder. Such records and books of account shall be maintained for a period of no less than
two (2) years following the period to which they pertain. LTI shall permit such records and books of account to be examined by Vical or Vical’s duly appointed agent, to the extent necessary for Vical to verify the amount of royalties
payable. Such examination shall be at Vical’s expense, during normal business hours, and upon ten (10) days’ prior written notice to LTI, except in the event that the results of the audit reveals a discrepancy in LTI’s favor of
[***] or more, then the audit fees shall be paid by LTI. 
 ARTICLE IX – PATENTS 
 9.1 Vical shall own the entire right, title, and interest in and to any Vical Improvements. Vical and LTI shall jointly own the entire right, title, and
interest in and to any Joint Improvements. LTI shall own the entire right, title, and interest in and to any LTI Improvements; provided, however, that LTI shall advise Vical of any such LTI Improvements within thirty (30) days of the recognized
discovery thereof [***]. 
  
  

	***	Confidential Treatment Requested 

  

 6 

 9.2 Vical may, at its option, file and prosecute patent applications, in its own name as owner, on the
Licensed Patent(s) and Vical Improvements, and in the names of the parties as joint owners, upon Joint Improvements. Should Vical notify LTI that it desires not to exercise this option with regard to an invention or disclosure or should it fail to
file a patent application within [***] of LTI’s reasonable written request that it do so, then, in that event, [***]. 
 ARTICLE X
– REPRESENTATIONS AND WARRANTIES 
 10.1 Vical represents and warrants that, to the best of its knowledge and information it is
the owner of the Know-how and the Licensed Patent(s), free of any liens, encumbrances, restrictions or other legal or equitable claims. Notwithstanding the preceeding, Vical makes no warranty as to the validity or scope of any of the Licensed
Patent(s), and nothing in this Agreement shall be construed as a warranty or representation that any Licensed Product(s) made, used or sold, or otherwise disposed of under any license granted by Vical under this Agreement is or will be free from
infringement of patents of third parties. Vical MAKES NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE WITH RESPECT TO THE LICENSED TECHNOLOGY COVERED BY THIS AGREEMENT. 
 10.2 LTI will indemnify and hold Vical harmless against any and all actions, suits, claims, demands, or prosecutions that may be brought against Vical to
the extent such actions, suits, claims, demands, or prosecutions arise out of the manufacture, use or sale of Licensed Product(s) by LTI, or any negligence, recklessness, or willful misconduct by LTI or LTI’s agents, except insofar as such
claims were caused solely by the negligence, recklessness, or willful misconduct of Vical. 
 ARTICLE XI – INFRINGEMENT 

 11.1 A party receiving knowledge of infringement of a Licensed Patent(s) shall notify the other party promptly. LTI shall have the right,
in its sole discretion, and at its sole expense, with counsel of its selection, to prosecute any patent infringement action or to defend any counterclaim of invalidity or action for declaratory judgment or interference. LTI shall have full control
over the conduct of any such proceedings and any recoveries therefore shall inure to its sole benefit. In the event LTI fails to initiate and pursue such legal action within a period of one hundred twenty (120) days after receipt of notice
thereof, Vical shall have the right to initiate legal action and shall in that event bear all costs and all recoveries therefore shall inure to its benefit. 
 11.2 If one party institutes or carries on a legal proceeding to enforce a Licensed Patent(s) against an alleged infringer, or to defend a Licensed Patent(s) in a declaratory judgment action, the other party shall
fully cooperate with, and supply all assistance reasonably requested by the party instituting and carrying on or defending such proceeding. 
  
  

	***	Confidential Treatment Requested 

  

 7 

 11.3 In the event LTI is sued by a third party for patent infringement allegedly resulting from
LTI’s manufacture, use or sale of Licensed Product(s), LTI shall promptly notify Vical. LTI shall, at its option, have full control of selection of counsel and conduct of the suit. Should LTI decide to defend it shall do so with the full
cooperation of Vical. From a date not less than six months following the date of institution of the suit LTI may place applicable royalties in an escrow account. Should LTI be deemed not infringing a third party’s patent(s) by a court of
competent jurisdiction, then all amounts paid into said escrow account shall be paid to Vical. Should LTI decide not to defend it shall provide Vical with timely notice thereof. Should Vical defend LTI’s actions under this Agreement then LTI
shall cooperate fully with Vical. Should LTI be deemed infringing a third party’s patent(s) and enjoined from exercising its rights under this Agreement by a court of competent jurisdiction, then LTI shall have the right to terminate this
Agreement with respect to the infringing patent claims and retain any royalties placed in the escrow account. 
 11.4 In the event a party
receiving knowledge of infringement of a Licensed Patent(s) promptly notifies the other party as required by Article 11.1 and thereafter neither party shall prosecute an infringer of a Licensed Patent(s) and the infringer’s activities are
allowed to continue without challenge for a period of up to six (6) months from the date of first notice, or in the event LTI is permanently enjoined by a court of competent jurisdiction from exercising its rights granted hereunder pursuant to
an infringement action brought by a third party, then LTI shall have the right to terminate this Agreement upon thirty (30) days written notice to Vical and in accordance with the terms of Article 12. 
 ARTICLE XII – TERMINATION 
 12.1
Vical may terminate this Agreement effective upon thirty (30) day’s prior written notice to LTI in the event LTI: 
 a) Commits a
material breach of this Agreement which is not cured within sixty (60) days of receipt of written notice thereof from Vical, or 
 b)
Should become insolvent, or a petition in bankruptcy is filed against LTI and is consented to, acquiesced in, or remains undismissed for ninety (90) days; makes a general assignment for the benefit of creditors, or a receiver is appointed for
LTI, and LTI does not return to solvency before the expiration of sixty (60) days. 
 12.2 LTI may terminate this Agreement effective
upon thirty (30) days written notice to Vical, 
 a) Should Vical commit a material breach of this Agreement; or 
  

 8 

 b) In accordance with Article 11.4. 
 12.3 Upon termination of this Agreement and except as otherwise expressly provided herein, all licenses granted to LTI under the terms of this Agreement
and, at Vical’s option, any sublicenses granted by LTI, shall terminate. 
 12.4 LTI shall have the right for up to [***] following
termination of this Agreement to dispose of all Licensed Product(s) then in its inventory, and shall pay royalties thereon, in accordance with the provisions of Article 6, as though this Agreement had not terminated. 
 12.5 Termination of this Agreement shall not affect any rights or obligations accrued prior to the effective date of such termination and specifically;

 a) LTI’s obligation: 
 i) To pay all royalties then accrued except in the event of termination under the provisions of Article 11.4. 
 ii) To make a
final report and payment under the provisions of Article 7.2; and 
 b) The provisions of Article 5, 8, 9, 10, 12 and 13. 
 c) The rights of either party as joint owners with respect to Joint Improvements or Joint Improvement Product(s). 
 12.6. The rights provided in this Article 12 shall be in addition to and without prejudice to any other rights which the parties may have with respect to
any breach or violations of the provisions of this Agreement. 
 12.7. Waiver by either party of a single default or breach or of a
succession of defaults or breaches shall not deprive such party of any right to terminate this Agreement pursuant to the terms hereof upon the occasion of any subsequent default or breach. 
 ARTICLE XIII – CONFIDENTIALITY 
 13.1. The parties shall be bound to
the confidentiality obligations agreed upon in the Confidential Disclosure Agreement between them dated July 7, 1989 and the parties agree that such obligations shall apply to the Know-how, the Licensed Patent(s), and the Improvements. The five
year term of nondisclosure shall begin with respect to Improvement(s) when the Improvement(s) are disclosed. 
 13.2. Prior to the public
disclosure by publication, presentation, or by other means, by either party of the results of activities under this 
  
  

	***	Confidential Treatment Requested 

  

 9 

 
Agreement, the prior written approval of the other party shall be obtained, which approval shall not be unreasonably withheld. Publication includes
submission of articles to LTI’s Focus publication. 
 ARTICLE XIV – COMMERCIAL APPLICATION 
 LTI shall use its good faith efforts to proceed with the development, manufacture, and sale of Licensed Product(s) and to diligently develop markets
therefor throughout the world and to meet such market demand. The parties acknowledge that LTI’s commercial application of the Licensed Product(s) is of the essence of this Agreement. 
 ARTICLE XV – ASSIGNMENT 
 This Agreement may not be assigned by
either party without the others written consent, except in the event of the sale or transfer of substantially the entire business of either party to which the Licensed Product(s) relate. 
 ARTICLE XVI – NOTICES 
 Any notice required by this Agreement shall
be sent by Registered or Certified U.S. Mail, or by telex or cable and shall be deemed delivered if sent to the following addresses of the respective parties or such other addresses as is furnished by proper notice to the other party: 
  

			
	FOR VICAL:	 	FOR LTI:
	Dr. Dannie King	 	Secy. Of Corporate Development
	President and COO	 	LIFE TECHNOLOGIES, INC.
	VICAL INCORPORATED	 	8717 Grovemont Circle
	9373 Towne Center Drive Suite 100	 	P.O. Box 6009
	San Diego, CA 92121	 	Gaithersburg, Maryland 20877

 ARTICLE XVII – MISCELLANEOUS 
 17.1 This Agreement may not be amended except by written agreement signed by both of the parties. 
 17.2 This Agreement shall be governed by and in accordance with the laws of the State of Maryland except where the federal laws of the United States are
applicable and have precedence. 
 17.3 The provisions of this Agreement shall be deemed separable. If any part of this Agreement is rendered
void, invalid, or unenforceable, such shall not affect the validity or enforceability of the remainder of this Agreement unless the part or parts which are void, invalid or unenforceable shall substantially impair the value of the entire Agreement
as to either party. 
  

 10 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed in duplicate originals by their duly
authorized representatives. 
  

									
	VICAL INCORPORATED	 		 	LIFE TECHNOLOGIES, INC.
					
	By:	 	 /s/    Martha J. Demski
	 		 	By:	 	 /s/    John Cogan

		 	Martha J. Demski	 		 		 	John Cogan
		 	Vice President and	 		 		 	Vice-President
		 	Chief Financial Officer	 		 		 	Corporate Development
					
	Date:	 	4/29/91	 		 	Date:	 	5/10/91

  

 11 

 AMENDMENT I 
 Life Technologies, Inc., a Delaware corporation having its principal place of business at 8400 Helgerman Court, Gaithersburg, MD 20884 (“LTI”) and Vical Incorporated, a Delaware corporation, having its principal place of business
at 9373 Towne Center Drive, Suite 100, San Diego, CA 92121 (“Vical”) hereby agree to amend the Agreement presently in effect (said Agreement having the Effective Date of 29 April 1991 and relating to technology described in US Patent
application Serial No. 07/511,219) in accordance with Paragraph 17.1 of the above Agreement as follows: 
  

	I.	In Paragraph 1.3 the passage “including in vivo experimentation in whole animals, but excluding use in humans,” is inserted after “research applications”
to complete the sentence. 

  

	II.	Paragraph 1.5 is hereby replaced in full by the following text: 

 “Improvements” shall mean any inventions, improvements or discoveries, on or related to the Know-how or the Licensed Patents made by LTI or Vical during the term of this Agreement. 
  

	III.	In all instances in which the term “Joint Improvements,” “Vical Improvements” or “LTI Improvements” appears, the word “Joint,”
“Vical” or “LTI” respectively, is to be deleted. 

  

	IV.	In Paragraph 3.1 a) the passage “made by Vical” is inserted after the word “Improvements.” 

  

	V.	Insert the following as a new paragraph in Article III to be designated 3.2: 

 LTI will during the term of this Agreement advise Vical of any Improvements made by LTI within thirty (30) days of the recognized discovery thereof. 
  

	VI.	Article IX – “Patents” is hereby replaced in full by the following text: 

  

	 	9.1	Vical shall own the entire right, title, and interest in and to any Improvements made solely by Vical. Vical and LTI shall jointly own the entire right, title, and interest in and
to any Improvements when there is inventorship by both LTI and Vical employees. LTI shall own the entire right, title, and interest in and to any Improvements made by LTI. 

	 	9.2	In the event a patentable invention is made which represents an Improvement and which is invented by employees of both LTI and Vical then the parties agree to negotiate in good
faith an arrangement concerning the prosecution of patent applications pertaining to such inventions. 

 This Amendment is agreed to have an
Effective Date of January 1, 1993. 
  

					
	AGREED TO BY:	 		 	
			
	Life Technologies Inc.	 		 	Vical Inc.
			
	 /s/    George E. Lowke
	 		 	 /s/    Alain B. Schreiber

	George E. Lowke	 		 	Alain B. Schreiber
	Vice President R&D	 		 	President and CEO
	4/20/93	 		 	5/4/93

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00154-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00154-of-00352.parquet"}]]